Company news
Tuhura Biosciences, Inc. (NASDAQ:HURA) news
Every Tuhura Biosciences, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
September 14, 2026
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
August 14, 2026
TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
July 22, 2026
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
June 15, 2026
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 15, 2026
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
May 12, 2026
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028
April 22, 2026
TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations
April 7, 2026
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
April 1, 2026
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
March 23, 2026
TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
February 27, 2026
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences
February 24, 2026
TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
February 17, 2026
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 12, 2026
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
February 2, 2026
TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
December 15, 2025
TuHURA Biosciences Provides Corporate Update Following Recent Financing
December 11, 2025
TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
December 9, 2025
TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
December 8, 2025
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
November 14, 2025
TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition
November 3, 2025
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
August 20, 2025
TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
August 14, 2025
TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
July 1, 2025
TuHURA Biosciences Completes Acquisition of Kineta
June 30, 2025
TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
June 24, 2025
TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
June 23, 2025
FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma
June 9, 2025
TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy
June 3, 2025
TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting
June 2, 2025
TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
May 15, 2025
TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference
May 13, 2025
TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)
May 5, 2025
TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting
April 28, 2025
TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting
April 8, 2025
TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management
April 7, 2025
TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
April 1, 2025
TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors
March 11, 2025
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
March 10, 2025
TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
February 19, 2025
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
December 12, 2024
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update
November 25, 2024
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
August 19, 2024
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
July 8, 2024
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.’s KVA12123 Novel anti-VISTA Checkpoint Inhibitor
July 8, 2024
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
June 3, 2024
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
June 3, 2024
Kintara Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference
May 8, 2023
Kintara Therapeutics to Present at the 2023 BIO CEO & Investor Conference
January 30, 2023